Started: 9/2018
Study Name: A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)
Indication: Pneumococcal
Principal Investigator: Luke Anschutz, Paul Bernhardson